US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NKGEN BIOTECH INC

0.1355

-0.0150-9.97%

Volume:294.93K

Turnover:47.10K

Market Cap:6.09M

PE:-0.07

High:0.2000

Open:0.1505

Low:0.1355

Close:0.1505

Loading ...

Overview Company News Filings

NKGen Biotech presents data from Phase 1/2a trial of troculeucel

NKGen to Transfer Listing to OTC Markets; Shares Drop

MT Newswires Live

NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

BRIEF-Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

THOMSON REUTERS

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

BRIEF-NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

NKGen administers first troculeucel dose under compassionate use program

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

THOMSON REUTERS

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

BRIEF-NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer’S Disease With Adventhealth Orlando As First East Coast Site

NKGen Biotech appoints Anita Fletcher as PI for Phase 2a troculeucel trial

NKGen Appoints DR. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease With Adventhealth Orlando as First East Coast Site

THOMSON REUTERS

BRIEF-NKGen Biotech Publishes Phase 1 Troculeucel Clinical Trial Results

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease

THOMSON REUTERS

NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease

BUZZ-NKGen jumps on FDA's 'fast track' designation for Alzheimer's drug

Sector Update: Health Care Stocks Softer Wednesday Afternoon

MT Newswires Live

NKGen Biotech Shares Rise After FDA Grants Fast-Track Status to Alzheimer's Drug Candidate

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NKGN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NKGN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NKGN\",,,,,undefined,":{"symbol":"NKGN","market":"US","secType":"STK","nameCN":"NKGEN BIOTECH INC","latestPrice":0.1355,"timestamp":1745611200000,"preClose":0.1505,"halted":0,"volume":294934,"delay":15,"floatShares":22651400,"shares":44947588,"eps":-1.99872,"marketStatus":"Pre-Mkt","change":-0.015,"latestTime":"04-25 16:00:00 EDT Delay","open":0.1505,"high":0.2,"low":0.1355,"amount":47102.95494999999,"amplitude":0.428571,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-1.99872,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745847000000},"marketStatusCode":1,"adr":0,"exchange":"PINK","adjPreClose":0.1355,"volumeRatio":4.522459428802772},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NKGN\",,,,,undefined,":{"symbol":"NKGN","floatShares":22651400,"roa":"-97.34%","roe":"--","lyrEps":-5.377227,"volumeRatio":4.522459428802772,"shares":44947588,"dividePrice":0,"high":0.2,"amplitude":0.428571,"preClose":0.1505,"low":0.1355,"week52Low":0.0983,"pbRate":"-0.13","week52High":2.19,"institutionHeld":0,"latestPrice":0.1355,"eps":-1.99872,"divideRate":0,"volume":294934,"delay":15,"ttmEps":-1.99872,"open":0.1505,"prevYearClose":0.6552,"prevWeekClose":0.1355,"prevMonthClose":0.18,"prevQuarterClose":0.18,"fiveDayClose":0.1275,"twentyDayClose":0.1608,"sixtyDayClose":0.486},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NKGN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525048922","title":"NKGen Biotech presents data from Phase 1/2a trial of troculeucel","url":"https://stock-news.laohu8.com/highlight/detail?id=2525048922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525048922?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:37","pubTimestamp":1744029423,"startTime":"0","endTime":"0","summary":"NKGen Biotech (NKGN) announced the oral presentation of updated Phase 1 clinical data from the Phase 1/2a trial evaluating troculeucel, cryopreserv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkgen-biotech-presents-data-from-phase-1-2a-trial-of-troculeucel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkgen-biotech-presents-data-from-phase-1-2a-trial-of-troculeucel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2517600318","title":"NKGen to Transfer Listing to OTC Markets; Shares Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2517600318","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517600318?lang=en_us&edition=fundamental","pubTime":"2025-03-05 02:47","pubTimestamp":1741114058,"startTime":"0","endTime":"0","summary":"NKGen Biotech  said Tuesday it expects its shares to be traded on the OTC Markets starting Wednesday following its delisting from Nasdaq.The company said Nasdaq determined to delist its shares after the close of trading on March 4 due to its continued failure to comply with the market value rule.NKGen said it has cancelled its 1-for-6 reverse stock split plan.NKGen shares fell over 48% in recent trading.Price: 0.26, Change: -0.25, Percent Change: -49.11","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2517607670","title":"NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2517607670","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517607670?lang=en_us&edition=fundamental","pubTime":"2025-03-05 02:11","pubTimestamp":1741111914,"startTime":"0","endTime":"0","summary":"NKGen Biotech (NKGN) announced that on March 3 it received notice that the Nasdaq Hearings Panel determined to delist the company’s common stock fr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkgen-biotech-moving-to-otc-markets-cancels-1-for-6-reverse-stock-split?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkgen-biotech-moving-to-otc-markets-cancels-1-for-6-reverse-stock-split?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSYW.SI","NKGN","USJW.SI","PSQ","QID","SQQQ","USAW.SI","NQmain","QLD",".IXIC","TQQQ","MNQmain","BK4139","NVIW.SI"],"gpt_icon":0},{"id":"2517602159","title":"NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented","url":"https://stock-news.laohu8.com/highlight/detail?id=2517602159","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517602159?lang=en_us&edition=fundamental","pubTime":"2025-03-05 02:00","pubTimestamp":1741111200,"startTime":"0","endTime":"0","summary":"Trading commencing on the OTC Markets on March 5, 2025.Trading expected to continue under ticker symbol “NKGN” for common stock and “NKGNW” for warrants.NKGen Biotech, Inc.  has regained compliance on its public reporting obligations with the filing of its most recent quarterly report on Form 10-Q on March 4, 2025; and intends to continue complying with all Securities and Exchange  reporting requirements.The Company has cancelled its previously announced 1-for-6 reverse stock split.Enrollment in randomized Phase 2a Alzheimer’s trial is expected to be completed by the end of Q2 with an initial readout planned for later in 2025.With the move away from Nasdaq and its minimum bid price requirement, the Company will not implement the previously announced 1-for-6 reverse stock split.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-inc-transition-nasdaq-180000301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","NKGN","LU0347712357.USD","NKGNW","LU1721428933.USD","LU2041044095.USD","USAW.SI","USJW.SI","AAIC","BK4585","TSYW.SI","BK4139","IE00BN0W2T93.GBP",".IXIC","LU2413666699.HKD","A","LU1165135440.EUR","SQQQ","IE00BN0W2W23.USD","LU2092937221.SGD","QID","BK4110","QLD","BK4567","NDAQ","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2413666426.HKD","LU2095319765.USD","BK4112","BK4121","LU2210149790.SGD","PSQ","MNQmain","TQQQ","IE00B3QW5Z07.USD","NVIW.SI","LU1543694498.USD","IE00BN0W2V16.EUR","NQmain","BK4588"],"gpt_icon":1},{"id":"2516363130","title":"BRIEF-Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2516363130","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516363130?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:18","pubTimestamp":1741011503,"startTime":"0","endTime":"0","summary":"BRIEF-Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use ProgramMarch 3 (Reuters) - Nkgen Biotech Inc NKGN.O:NKGEN BIOTECH ANNOUN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0CG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2516633982","title":"NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2516633982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516633982?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006820,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0CG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2516563342","title":"NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2516563342","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516563342?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"NKGen explores the use of troculeucel as a potential treatment option for post-stroke patients.SANTA ANA, Calif., March 03, 2025  -- NKGen Biotech, Inc.  , a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer  cell therapeutics, today announced the administration of troculeucel, an expanded autologous NK cell therapy, in a stroke patient under a single compassionate use, Investigational New Drug  cleared by the U.S. Food and Drug Administration .Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-announces-administration-first-130000058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKGNW","BK4139","NKGN"],"gpt_icon":0},{"id":"2513293907","title":"BRIEF-NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2513293907","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513293907?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:11","pubTimestamp":1740147109,"startTime":"0","endTime":"0","summary":"BRIEF-NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use ProgramFeb 21 (Reuters) - Nkgen Biotech Inc NKGN.O:NKGE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nFWN3PC18V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2513626036","title":"NKGen administers first troculeucel dose under compassionate use program","url":"https://stock-news.laohu8.com/highlight/detail?id=2513626036","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513626036?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:16","pubTimestamp":1740143787,"startTime":"0","endTime":"0","summary":"NKGen Biotech (NKGN) announced the administration of troculeucel, an expanded autologous NK cell therapy, in an FTD patient under a single compassi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkgen-administers-first-troculeucel-dose-under-compassionate-use-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkgen-administers-first-troculeucel-dose-under-compassionate-use-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2513267378","title":"NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2513267378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513267378?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:01","pubTimestamp":1740142867,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nFWN3PC18V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2513267640","title":"NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2513267640","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513267640?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:00","pubTimestamp":1740142800,"startTime":"0","endTime":"0","summary":"NKGen takes a meaningful step towards potential treatment for frontotemporal dementia  patients with limited treatment options.It is estimated that about 60,000 people in the U.S. are currently living with FTD. Up to 40% of FTD cases have a genetic component and the patient receiving troculeucel is known to carry the C9orf72 gene mutation. Currently, there is no cure for FTD and, unfortunately, no current treatments are available that slow or stop disease progression.NKGen has begun to explore the potential therapeutic role of troculeucel for the treatment of FTD in collaboration with Mario Mendez, M.D., Ph.D., Director of the Behavioral Neurology Program at the David Geffen School of Medicine at UCLA and Jessica Rexach, M.D., Ph.D., Director of the Rexach Lab at UCLA Department of Neurology. This single, FDA-cleared, IND compassionate use will be the initial step towards a future full IND application as the dosing of the first FTD patient is part of NKGen’s ongoing effort to explore t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-announces-administration-first-130000113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKGN","NKGNW"],"gpt_icon":0},{"id":"2512248550","title":"BRIEF-NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer’S Disease With Adventhealth Orlando As First East Coast Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2512248550","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512248550?lang=en_us&edition=fundamental","pubTime":"2025-02-19 23:05","pubTimestamp":1739977559,"startTime":"0","endTime":"0","summary":"BRIEF-NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer’S Disease With Adventhealth Orlando As First East Coast SiteFeb ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA4PGW5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2512104494","title":"NKGen Biotech appoints Anita Fletcher as PI for Phase 2a troculeucel trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2512104494","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512104494?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:10","pubTimestamp":1739970637,"startTime":"0","endTime":"0","summary":"NKGen Biotech (NKGN) announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator for its Phase 2a clinical trial ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkgen-biotech-appoints-anita-fletcher-as-pi-for-phase-2a-troculeucel-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkgen-biotech-appoints-anita-fletcher-as-pi-for-phase-2a-troculeucel-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PI","BK4141","BK4139","NKGN","LU1878469433.USD"],"gpt_icon":0},{"id":"2512101419","title":"NKGen Appoints DR. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease With Adventhealth Orlando as First East Coast Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2512101419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512101419?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA4PGW5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2511547537","title":"BRIEF-NKGen Biotech Publishes Phase 1 Troculeucel Clinical Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2511547537","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511547537?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:14","pubTimestamp":1739452477,"startTime":"0","endTime":"0","summary":"BRIEF-NKGen Biotech Publishes Phase 1 Troculeucel Clinical Trial Results Feb 13 (Reuters) - Nkgen Biotech NKGN.O:NKGEN BIOTECH ANNOUNCES PUBLICATION OF PHASE 1 TROCULEUCEL CLINICAL TRIAL RESULTS FOR T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA9MNRKT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NKGN"],"gpt_icon":0},{"id":"2511425135","title":"NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2511425135","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511425135?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:00","pubTimestamp":1739451601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA9MNRKT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKGN","BK4139"],"gpt_icon":0},{"id":"2511542196","title":"NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2511542196","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511542196?lang=en_us&edition=fundamental","pubTime":"2025-02-13 21:00","pubTimestamp":1739451600,"startTime":"0","endTime":"0","summary":"The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse events following troculeucel therapy.Troculeucel therapy was well-tolerated and resulted in beneficial effects on protein aggregate levels and neuroinflammatory biomarkers in the cerebrospinal fluid, with decreases in pTau181 and GFAP appearing to be dose dependent.A larger trial with a higher dosing/duration has been initiated in the U.S. and is on-going.The publication showcases important context and further validation of the findings from the Company’s Phase 1 clinical study, which evaluated its expanded autologous NK cell therapy, troculeucel, in subjects with either mild, moderate, or severe AD . The clinical trial information in this publication includes comprehensive details on troculeucel preparation, preclinical studies elucidating the mechanism of action, clinical trial design, and trial results . Final Results of the Phase 1 trial ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkgen-biotech-announces-publication-phase-130000229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NKGN","NKGNW"],"gpt_icon":0},{"id":"2511586960","title":"BUZZ-NKGen jumps on FDA's 'fast track' designation for Alzheimer's drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2511586960","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511586960?lang=en_us&edition=fundamental","pubTime":"2025-02-13 02:56","pubTimestamp":1739386605,"startTime":"0","endTime":"0","summary":"BUZZ-NKGen jumps on FDA's 'fast track' designation for Alzheimer's drug ** Drug developer NKGen Biotech's shares NKGN.O surge 26% to 47 cents  ** Company says U.S. FDA has granted \"fast track\" designa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nL4N3P31KW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NKGN"],"gpt_icon":1},{"id":"2511458503","title":"Sector Update: Health Care Stocks Softer Wednesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2511458503","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511458503?lang=en_us&edition=fundamental","pubTime":"2025-02-13 02:46","pubTimestamp":1739386016,"startTime":"0","endTime":"0","summary":"Health care stocks were softer Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  each declining about 0.2%.The iShares Biotechnology ETF  eased 0.1%.In corporate news, CVS Health  reported better-than-expected Q4 results and projected higher 2025 earnings. The shares jumped about 16%.Biogen  guided for a decline in earnings and revenue for 2025 amid ongoing challenges in its multiple sclerosis product category, despite reporting stronger-than-expected Q4 results. Its shares fell 5.7%.NKGen Biotech  shares jumped 37% after it said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0211331839.USD","IE00BKVL7J92.USD","NKGN","XLV","IE00B19Z9Z06.USD","IE00B894F039.SGD","LU0006061336.USD","IE00BSNM7G36.USD","BK4581","BIIB","BK4139","BK4196","LU0070302665.USD","LU1059921491.USD","LU0061475181.USD","BK4550","BK4585","LU0320765992.SGD","LU0109394709.USD","LU0072461881.USD","BK4532","LU0320765489.SGD","BK4588","CVS.AU","BK4533","LU1571399168.USD","LU0162691827.USD","LU0234570918.USD","LU1699723380.USD","IBB","IE00B19Z9P08.USD","IE00BZ1G4Q59.USD","CVS","LU0208291251.USD","LU0889565916.HKD","BK4504"],"gpt_icon":0},{"id":"2510430690","title":"NKGen Biotech Shares Rise After FDA Grants Fast-Track Status to Alzheimer's Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2510430690","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510430690?lang=en_us&edition=fundamental","pubTime":"2025-02-12 23:24","pubTimestamp":1739373869,"startTime":"0","endTime":"0","summary":"NKGen Biotech  shares rose by more than 24% in recent Wednesday trading after the company said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.The designation follows positive phase 1 trial results, which showed early signs of clinical benefit for patients treated with troculeucel, the company said.NKGen is currently enrolling patients its phase 2a trial for moderate Alzheimer's disease patients and plans to release updated clinical data by the end 2025.Price: 0.47, Change: +0.09, Percent Change: +24.01","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4585","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","BK4567","FAST","IE00B5TLWC47.USD","NKGN","BK4104","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NKGN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-05","symbol":"NKGN","reason":null,"defaultRemindTime":1741185000000,"announcedDate":"2025-03-04","type":"delisting","dateTimestamp":1741150800000},{"market":"US","date":"2024-09-12","symbol":"NKGN","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1726113600000,"reportTimeType":"post","actualEps":-0.67},{"market":"US","date":"2024-05-20","symbol":"NKGN","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1716177600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2024-04-16","symbol":"NKGN","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1713240000000,"reportTimeType":"post","actualEps":-1.68},{"market":"US","date":"2023-11-14","symbol":"NKGN","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"post","actualEps":-2.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NKGN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NKGN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NKGN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NKGN","date":"2025-03-03","current":-0.271714,"percent":0.653374,"low":-3.085872,"twenty":-1.017152,"median":-0.369534,"eighty":-0.200359,"high":-0.092159,"avg":-0.615092,"sd":0.608265,"marketCap":23979538},"quantilePoints":[{"date":"2023-10-13","current":-2.180674,"twenty":-2.944804,"median":-2.349548,"eighty":-2.292278,"marketCap":65010258},{"date":"2023-10-20","current":-2.202701,"twenty":-2.461546,"median":-2.202701,"eighty":-2.198296,"marketCap":65666928},{"date":"2023-10-27","current":-2.775403,"twenty":-2.690232,"median":-2.202701,"eighty":-2.196827,"marketCap":82740329},{"date":"2023-11-03","current":-2.239413,"twenty":-2.543386,"median":-2.202701,"eighty":-2.183611,"marketCap":66761376},{"date":"2023-11-10","current":-2.276125,"twenty":-2.411223,"median":-2.257769,"eighty":-2.196827,"marketCap":67855825},{"date":"2023-11-17","current":-2.114593,"twenty":-2.362764,"median":-2.202701,"eighty":-2.138088,"marketCap":63040250},{"date":"2023-11-24","current":-1.139241,"twenty":-2.35689,"median":-2.202701,"eighty":-2.099908,"marketCap":64134699},{"date":"2023-12-01","current":-1.341388,"twenty":-2.349548,"median":-2.188016,"eighty":-1.310321,"marketCap":75514778},{"date":"2023-12-08","current":-1.321986,"twenty":-2.334863,"median":-2.143962,"eighty":-1.283104,"marketCap":74422518},{"date":"2023-12-15","current":-1.463905,"twenty":-2.320179,"median":-2.110922,"eighty":-1.310321,"marketCap":82411994},{"date":"2023-12-22","current":-1.100359,"twenty":-2.276125,"median":-2.063931,"eighty":-1.197564,"marketCap":61945802},{"date":"2023-12-29","current":-1.193676,"twenty":-2.254098,"median":-1.734182,"eighty":-1.172679,"marketCap":67199156},{"date":"2024-01-05","current":-1.073141,"twenty":-2.239413,"median":-1.426967,"eighty":-1.161793,"marketCap":60413573},{"date":"2024-01-12","current":-1.042036,"twenty":-2.232071,"median":-1.331687,"eighty":-1.123688,"marketCap":58662455},{"date":"2024-01-19","current":-0.989545,"twenty":-2.202701,"median":-1.318097,"eighty":-1.096471,"marketCap":55707443},{"date":"2024-01-26","current":-0.913726,"twenty":-2.202701,"median":-1.312265,"eighty":-1.073141,"marketCap":51439093},{"date":"2024-02-02","current":-0.624055,"twenty":-2.202701,"median":-1.304489,"eighty":-1.065365,"marketCap":35131806},{"date":"2024-02-09","current":-0.625999,"twenty":-2.202701,"median":-1.197564,"eighty":-1.022595,"marketCap":35241251},{"date":"2024-02-16","current":-0.585173,"twenty":-2.195359,"median":-1.180067,"eighty":-0.989545,"marketCap":32942908},{"date":"2024-02-23","current":-0.388819,"twenty":-2.183611,"median":-1.166459,"eighty":-0.878514,"marketCap":21888976},{"date":"2024-03-01","current":-0.309889,"twenty":-2.157179,"median":-1.139241,"eighty":-0.629887,"marketCap":17445513},{"date":"2024-03-08","current":-0.750421,"twenty":-2.145431,"median":-1.115911,"eighty":-0.62561,"marketCap":42245723},{"date":"2024-03-15","current":-0.723204,"twenty":-2.138088,"median":-1.096471,"eighty":-0.629109,"marketCap":40713495},{"date":"2024-03-22","current":-0.863179,"twenty":-2.118998,"median":-1.079771,"eighty":-0.629887,"marketCap":48593526},{"date":"2024-03-28","current":-0.699875,"twenty":-2.110188,"median":-1.071197,"eighty":-0.63222,"marketCap":39400156},{"date":"2024-04-05","current":-0.503373,"twenty":-2.102845,"median":-1.065365,"eighty":-0.629887,"marketCap":28337889},{"date":"2024-04-12","current":-0.503373,"twenty":-2.078322,"median":-1.053701,"eighty":-0.610089,"marketCap":28337889},{"date":"2024-04-19","current":-0.338204,"twenty":-2.028247,"median":-1.022595,"eighty":-0.596449,"marketCap":19039519},{"date":"2024-04-26","current":-0.54434,"twenty":-1.680126,"median":-1.008986,"eighty":-0.567673,"marketCap":45155173},{"date":"2024-05-03","current":-0.362893,"twenty":-1.441742,"median":-0.989545,"eighty":-0.506509,"marketCap":30103448},{"date":"2024-05-10","current":-0.343649,"twenty":-1.375643,"median":-0.907894,"eighty":-0.49327,"marketCap":28507053},{"date":"2024-05-17","current":-0.320045,"twenty":-1.341404,"median":-0.877643,"eighty":-0.471192,"marketCap":26548978},{"date":"2024-05-24","current":-0.546156,"twenty":-1.329747,"median":-0.84957,"eighty":-0.471192,"marketCap":43700088},{"date":"2024-05-31","current":-0.488338,"twenty":-1.321986,"median":-0.832073,"eighty":-0.458565,"marketCap":39073844},{"date":"2024-06-07","current":-0.426129,"twenty":-1.318875,"median":-0.765974,"eighty":-0.449088,"marketCap":34096284},{"date":"2024-06-14","current":-0.410577,"twenty":-1.314209,"median":-0.762086,"eighty":-0.443054,"marketCap":32851894},{"date":"2024-06-21","current":-0.373252,"twenty":-1.314209,"median":-0.746533,"eighty":-0.419908,"marketCap":29865358},{"date":"2024-06-28","current":-0.385693,"twenty":-1.313431,"median":-0.743262,"eighty":-0.41586,"marketCap":30860870},{"date":"2024-07-05","current":-0.407466,"twenty":-1.311876,"median":-0.715734,"eighty":-0.407466,"marketCap":32603016},{"date":"2024-07-12","current":-0.323485,"twenty":-1.309543,"median":-0.686267,"eighty":-0.404316,"marketCap":25883310},{"date":"2024-07-15","current":-0.298601,"twenty":-1.308766,"median":-0.672658,"eighty":-0.402482,"marketCap":23892287},{"date":"2024-08-02","current":-0.344629,"twenty":-1.307988,"median":-0.662937,"eighty":-0.401328,"marketCap":27575111},{"date":"2024-08-09","current":-0.328524,"twenty":-1.3041,"median":-0.629887,"eighty":-0.395025,"marketCap":26286554},{"date":"2024-08-16","current":-0.281822,"twenty":-1.29088,"median":-0.625027,"eighty":-0.387569,"marketCap":22549740},{"date":"2024-08-23","current":-0.257988,"twenty":-1.23178,"median":-0.609553,"eighty":-0.372408,"marketCap":20642676},{"date":"2024-08-30","current":-0.245878,"twenty":-1.195231,"median":-0.60267,"eighty":-0.368424,"marketCap":19673682},{"date":"2024-09-06","current":-0.246103,"twenty":-1.18901,"median":-0.586145,"eighty":-0.359064,"marketCap":19691721},{"date":"2024-09-13","current":-0.280405,"twenty":-1.180456,"median":-0.583229,"eighty":-0.344629,"marketCap":22436347},{"date":"2024-09-20","current":-0.171296,"twenty":-1.176568,"median":-0.54352,"eighty":-0.33213,"marketCap":15117415},{"date":"2024-09-27","current":-0.158394,"twenty":-1.168014,"median":-0.519442,"eighty":-0.32312,"marketCap":13978747},{"date":"2024-10-04","current":-0.15587,"twenty":-1.150906,"median":-0.512641,"eighty":-0.317872,"marketCap":13755964},{"date":"2024-10-11","current":-0.115199,"twenty":-1.139241,"median":-0.503373,"eighty":-0.311624,"marketCap":10166683},{"date":"2024-10-18","current":-0.285679,"twenty":-1.139241,"median":-0.49881,"eighty":-0.304184,"marketCap":25212023},{"date":"2024-10-25","current":-0.15798,"twenty":-1.131465,"median":-0.489912,"eighty":-0.283365,"marketCap":13942248},{"date":"2024-10-31","current":-0.117128,"twenty":-1.118245,"median":-0.487643,"eighty":-0.276991,"marketCap":10336929},{"date":"2024-11-08","current":-0.110272,"twenty":-1.10969,"median":-0.473878,"eighty":-0.260707,"marketCap":9731840},{"date":"2024-11-15","current":-0.113088,"twenty":-1.099581,"median":-0.451012,"eighty":-0.251399,"marketCap":9980359},{"date":"2024-11-22","current":-0.137738,"twenty":-1.094916,"median":-0.449385,"eighty":-0.246161,"marketCap":12155796},{"date":"2024-11-29","current":-0.163245,"twenty":-1.088694,"median":-0.443706,"eighty":-0.241369,"marketCap":14406870},{"date":"2024-12-06","current":-0.183569,"twenty":-1.080918,"median":-0.426129,"eighty":-0.205158,"marketCap":16200525},{"date":"2024-12-13","current":-0.201934,"twenty":-1.078624,"median":-0.416878,"eighty":-0.201567,"marketCap":17821298},{"date":"2024-12-20","current":-0.230625,"twenty":-1.073141,"median":-0.415128,"eighty":-0.198751,"marketCap":20353306},{"date":"2024-12-27","current":-0.356731,"twenty":-1.070031,"median":-0.407466,"eighty":-0.199796,"marketCap":31482613},{"date":"2025-01-03","current":-0.282006,"twenty":-1.069253,"median":-0.405058,"eighty":-0.200963,"marketCap":24887868},{"date":"2025-01-10","current":-0.233645,"twenty":-1.067698,"median":-0.401382,"eighty":-0.201714,"marketCap":20619833},{"date":"2025-01-17","current":-0.187977,"twenty":-1.065365,"median":-0.401246,"eighty":-0.19973,"marketCap":16589511},{"date":"2025-01-24","current":-0.212259,"twenty":-1.063032,"median":-0.395025,"eighty":-0.198914,"marketCap":18732533},{"date":"2025-01-31","current":-0.248031,"twenty":-1.053701,"median":-0.388819,"eighty":-0.199649,"marketCap":21889475},{"date":"2025-02-07","current":-0.229187,"twenty":-1.051368,"median":-0.37948,"eighty":-0.199991,"marketCap":20226414},{"date":"2025-02-14","current":-0.391604,"twenty":-1.038148,"median":-0.373267,"eighty":-0.199649,"marketCap":34560200},{"date":"2025-02-21","current":-0.228168,"twenty":-1.022595,"median":-0.373252,"eighty":-0.199975,"marketCap":20136519},{"date":"2025-02-28","current":-0.272579,"twenty":-1.018707,"median":-0.369837,"eighty":-0.200057,"marketCap":24055949},{"date":"2025-03-03","current":-0.271714,"twenty":-1.017152,"median":-0.369534,"eighty":-0.200359,"marketCap":23979538}],"updateTime":1745836639642}}}